Mikhail Blagosklonny is an expert in anti-aging medicine and oncology. The scientist has spent his career studying aging and cancer. In addition, he has made exceptional contributions to the fields. Mikhail is an oncology professor at the New York’s Roswell Park Cancer Institute.
Blagosklonny is an alumnus of the First Pavlov State Medical University of St. Petersburg. At the University, he pursued internal medicine for his M.D. After graduating, he enrolled for experimental medicine and cardiology doctorate. His sound educational background saw him earn a position at Ordway Research Institute in Albany, New York. The expert served at the Institute as a senior scientist until 2009 when he moved to the Roswell Park Cancer Institute as the professor of oncology. Since then, he has been at Roswell Park.
Throughout his career, Blagosklonny has been interested in cancer and targeted cancer therapies. His research in targeted cancer therapies has focused on how normal cells can be protected from the damages caused by cancer cells. He is also involved in studying the underlying mechanisms of aging and drugs that can be used to slow down aging. This field is called biogerontology.
Mikhail Blagosklonny is known for his hypothesis that claims that TOR signaling plays a critical role in aging and cancer. According to his hypothesis, it is possible to use cancer drugs such as rapamycin to treat aging. Although some scientists are still investigating his claims, Blagosklonny remains optimistic about its success. He has been the most vocal proponent of using rapamycin as an anti-aging drug. Source: https://www.linkedin.com/in/mikhail-blagosklonny-91abb531
Mikhail’s presence at Roswell Park Cancer Institute has served to provide other experts with new outlook at anticancer strategies, cancer therapy, and methods of cancer prevention. These insights will help the institute accelerate and broaden its research. Mikhail Blagosklonny’s research at the firm will also involve looking at the ways in which healthy cells could be protected from radio and chemotherapies. In addition, it will focus on how slowing down organismal aging could prevent cancer, and selective combination of anti-cancer drugs. The scientist will also continue working on his TOR Signaling hypothesis.
Apart from his research on aging and oncology, Blagosklonny is an editor-in-chief of different publications such as Aging, Cell Cycle, and Oncotarget. He is also Cancer Biology & Therapy’s associate editor and editorial board member of Cell Death & Differentiation. The scientist’s editorial roles have seen him edit many publications in the fields of aging and oncology. This opportunity has exposed him to new and radical approaches in the field.
Read more about Mikhail Blagosklonny Research Gate